NEW YORK – Following the results of a validation study, startup Nephrosant plans to launch its urine-based QiSant assay — which provides a threshold score for kidney transplant rejection risk and a numerical score for the intensity of rejection — as a laboratory-developed test later this year.
The San Francisco-based firm believes the serial monitoring assay could guide the clinical use of immunosuppressive drugs and other therapies to prevent a recipient's body from rejecting a donated kidney.